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The parasite Plasmodium falciparum is the main agent responsible for malaria. In this study,
we exploited a recently published chemical library from GlaxoSmithKline (GSK) that had
previously been conﬁrmed to inhibit parasite growth of the wild type (3D7) and the multi-drug
resistance (D2d) strains, in order to uncover the weak links in the proteome of the parasite.
We predicted 293 proteins of P. falciparum, including the six out of the seven veriﬁed targets
for P. falciparum malaria treatment, as targets of 4645 GSK active compounds. Furthermore, we
prioritized druggable targets, based on a number of factors, such as essentiality for growth,
lack of homology with human proteins, and availability of experimental data on ligand
activity with a non-human homologue of a parasite protein. We have additionally prioritized
predicted ligands based on their polypharmacology proﬁle, with focus on validated essential
proteins and the eﬀect of their perturbations on the metabolic network of P. falciparum,
as well as indication of drug resistance emergence. Finally, we predict potential oﬀ-target eﬀects
on the human host with associations to cancer, neurological and dermatological disorders, based
on integration of available chemical–protein and protein–protein interaction data. Our work
suggests that a large number of the P. falciparum proteome is potentially druggable and could
therefore serve as novel drug targets in the ﬁght against malaria. At the same time, prioritized
compounds from the GSK library could serve as lead compounds to medicinal chemists for
further optimization.
Introduction
Malaria is one of the most hazardous tropical parasitic
diseases in humans and can be dated back to 2800 BC.1,2
Fifty years ago, malaria had been almost eliminated from
many areas of the world through a combination of long acting
pharmaceuticals and vector control interventions.3,4 However,
the global spread of drug resistance to all but one of the ﬁve
major classes of anti-malarial drugs,5,6 together with a collapse
of vector control programs, resulted in resurgence in disease
morbidity and mortality by the 1980s. About 50% of the
world’s population live in endemic areas, situated mostly
in Africa, Asia, and South America.7 With approximately
250 million cases and 850 000 attributed deaths reported
globally in 2009,7 malaria is one of the most severe infectious
diseases primarily aﬀecting the world’s most disadvantaged
populations and killing more under-5-year olds than any other
infectious agent. Up to now no approved vaccine is available,
while researchers in Cambodia have reported the ﬁrst signs of
resistance to artemisinins, the essential ingredient of existing
malarial treatments for 100 million patients annually.8 The
grim malaria statistics could rise even higher if resistance to
the existing anti-malarial drugs develops further.9
Malaria is generally caused by four apicomplexan parasites
of the genus Plasmodium, including Plasmodium falciparum
(most lethal), P. vivax, P. ovale, and P malariae. The malaria
parasite P. falciparum exhibits a complex life cycle that involves
infection of a vertebrate human host by the female Anopheles
mosquito during a blood meal. Unlike the human host,
P. falciparum lacks the ability to salvage pyrimidine bases and
thus is entirely dependent on de novo biosynthesis.10,11 Clinical
manifestations begin when parasites enter erythrocytes. The
erythrocytic cycle of P. falciparum involves a massive ampliﬁca-
tion of the parasite population through periodic cycles of
invasion, growth, division and egress from erythrocytes.
In 2002, the genome of P. falciparum was sequenced,12
renewing hope that progress towards reducing the burden of
malaria would be greatly accelerated by understanding the
biology of the parasite at the molecular level. Rational drug
design was introduced in malaria research at the same time,
with great optimism that new drugs would emerge based on
the knowledge of the biological target. Although our under-
standing of the parasite’s biology has signiﬁcantly increased in
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the last decade, no new class of antimalarials has been intro-
duced into clinical practice since 1996.16 Approximately half of
the predicted proteins to date are of uncharacterized function,
with little sequence similarity outside the Plasmodium genus,
while a large number of genes and gene families are unique
to P. falciparum.12,13 Amongst theB5300 proteins encoded in
P. falciparum genome, only seven, namely PF10_0084 (tubulin
beta chain), PF10_0289 (adenosine diaminase), PFD0830w
(bifunctional dihydrofolate reductase-thymidylate synthase),
PFE0520c (topoisomerase I), PFF0160c (dihydroorotate
dehydrogenase), PF10_0334 (ﬂavoprotein subunit of succinate
dehydrogenase) and PFI1020c (inosine-50-monophosphate
dehydrogenase), are currently veriﬁed drug targets.14
Clinical experience has shown that drugs targeting a single
molecular pathway, monotherapy or highly mutable drug
targets, have each led to resistance and are undesirable in
eﬀective long-term strategies against multi-drug resistant
malaria.15 Parasite-based screening is an alternative approach
to rational drug design with the advantage of identifying
compounds that may act on more than one molecular target
or pathway. In such compound screening endeavor that was
recently published, Gamo et al.16 used the GlaxoSmithKline
(GSK) in-house chemical library to evaluate almost 2 million
compounds against asexual blood stage P. falciparum. Setting
the threshold for growth inhibition to greater than 80%,
at a concentration cut-oﬀ of 2 micromolar, the authors
identiﬁed more than 13 500 active compounds, 8000 of these
being equally active against multi-drug-resistant P. falciparum
parasites.
Gamo and collaborators, however, did not identify the
parasite drug targets, which is the speciﬁc aim of the present
study. For anti-infectious drug discovery, where pharma-
ceutically investigated targets only represent a small portion
of the whole pathogen’s genome, it is more challenging to
establish a proteome-wide drug-target network.17 Here we use
the wealth of information from the GSK compound collection
to link the proteome of P. falciparum with the bioactive
chemical space, following a systems chemical biology approach
fueled by similarity-based virtual screening and protein homo-
logue analysis. One of our primal aims is to identify druggable
proteins in P. falciparum and to prioritize them on the basis of
essentiality for growth, lack of homology with human proteins
and availability of experimental data that support prediction
of binding to an active GSK compound. At the same time, we
aim to identify compounds from the GSK collection that are
capable of escaping drug resistance, have polypharmacology
proﬁles that cover multiple essential targets and perturb
diﬀerent points of the parasite’s metabolic network. Our
results could also be seen in the light of drug synergy, and
assist in the selection of compounds with synergistic eﬀects
that could be used in a combinatorial antimalarial therapy.
Finally, we evaluate in silico potential toxic and oﬀ-target
interactions of the predicted polyactive GSK compounds with
the human proteome, by integrating available, experimental
information from chemical–protein and protein–protein inter-
action databases. Our study is the ﬁrst to follow up on the
published GSK library of compounds and contributes to the
selection of durable anti-malarial drug targets and chemical
molecules for further preclinical evaluation.
Results and discussion
The druggable landscape of the P. falciparum proteome
The chemical library of compounds with anti-malaria properties
from the GSK in-house collection is the largest published to
date, but it lacks information regarding interactions between
the tested compounds and the parasite’s proteome. Since the
anti-malarial properties of the 13 533 GSK compounds are
based on an in vivo screen, we initially ventured a concerted
systems chemical biology approach to create an interaction
map of the active compounds from GSK on the parasite’s
protein space. ChemProt,18 a database compiled in-house from
multiple chemical–protein annotation resources, with more
than 700 000 unique chemicals and biological annotation for
30 578 targets, was surveyed in two ways: ﬁrstly, for direct
experimental bioactivity information concerning the 13 533
GSK compounds, and secondly, for predicted bioactivities
via structural similarities with compounds from ChemProt, on
the premise that structurally similar molecules are expected to
exhibit similar biological activities.
Not surprisingly, considering the uniqueness of this dataset,
there are only 205 GSK compounds with recorded experi-
mental activity in ChemProt, involving 86 protein targets, 51
of which have a homologue in P. falciparum. The target space
of the GSK compounds was subsequently enriched with 250
protein targets in the proteome of P. falciparum associated
with 4495 GSK compounds that have Tanimoto coeﬃcient
similarity of at least 0.85 with a bioactive compound in
ChemProt. It has been previously reported in the scientiﬁc
literature that compounds with structural similarity above this
threshold tend to exert similar biological activities.19 The full
network of GSK compounds and the druggable P. falciparum
proteome consists of 4645 unique small molecules and 293
protein targets. The genomic location of the 293 proteins was
identiﬁed using PlasmoDB (www.plasmodb.org/) (Fig. 1A).
The genomic location of the genes coding for the 293 protein
targets, taking into consideration the size of the chromosome,
indicates with 95% conﬁdence a preference for chromosomes
3, 13 and 14 while lower preference is indicated for chromo-
somes 4, 7, 8, 9 (Fig. 1B). To conceptualize the sensitivity of
P. falciparum to the GSK compounds, we assigned GO-terms
to the 293 protein targets using Blast2GO (www.blast2go.org/).
The molecular function annotation revealed that the majority
of the protein targets are involved in nucleotide binding,
followed by protein binding, transporter activity, transcriptional
regulation and protein kinase activity, while their involvement
into biological processes includes amino-acid and lipid meta-
bolism, protein modiﬁcation and translation (see File S1, ESIw).
Protein kinases are considered as particularly attractive
drug-target classes, not only because it is well established that
small molecules can bind to their catalytic cleft but also
because protein phosphorylation is one of the most important
and pleiotropic modes of regulation of cell physiology.20 Lipid
metabolism, which is almost nonfunctional in the uninfected
erythrocyte, is dramatically elevated during the intraerythro-
cytic development of the malaria parasite contributing mainly
to membrane biogenesis. The unique features in lipid meta-
bolism of P. falciparum are ideal for malaria chemotherapeutic
purposes.21 Transporters, providing essential nutrients and
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disposing toxic wastes as well as being components of important
regulatory pathways in P. falciparum, are excellent targets.
Transporters can provide delivery routes for drugs that target
essential parasite mechanisms but are also involved in mediating
drug resistance.22,23
A detailed matrix of all predicted interactions between GSK
compounds and the P. falciparum proteome is provided in
File S2 (ESIw). It is worth noting that six out of the seven
veriﬁed targets for P. falciparum malaria treatment, namely
PF10_0084, PF10_0289, PFD0830w, PFE0520c, PFF0160c,
and PFI1020c, are predicted to interact with compounds from
the GSK library. 2133 GSK compounds (almost half of the
total number of predictions) selectively target one amongst a
subset of 130 proteins of P. falciparum. This ﬁnding could lead
to the assumption that these 130 proteins are important for the
growth of the parasite, while the fact that ﬁve of the veriﬁed
malaria targets are included in this list reinforces this state-
ment. 77 of these do not have a human homologue in NCBI
HomoloGene,24 which is another desirable feature when
selecting parasitic targets for drug development.
We acknowledge here that our ability to identify protein
targets in the proteome of P. falciparum that may be important
for the growth of the parasite is limited by the chemical
and target space covered by the ChemProt database. If a
P. falciparum protein does not carry adequate sequence similarity
with any of the proteins that are included in the repository, we
will be, of course, unable to identify it as a potential drug
target. Similarly, if a GSK compound does not have adequate
structural similarity with any of the ligands in ChemProt, we
fail to capture its protein target(s) in the P. falciparum
proteome. Nevertheless, by using the present systems chemical
biology approach we manage to move away from conven-
tional methods that stay in the space of the known antimalarial
drugs and their known targets. To our knowledge, this is the
ﬁrst drug–target network that covers this many proteins in the
P. falciparum proteome and all compounds that have shown
antimalarial activity on in vitro parasite screens.
Design of multi-target therapies against malaria
Multi-target therapy is believed to be more eﬀective than
single-target therapy when treating infectious diseases.17 A
promising drug candidate should, therefore, not be selective to
a single target, but rather be polyactive, i.e. have an activity
proﬁle that includes more than one protein essential for the
parasite—preferably with no human homologues—in order to
avoid drug resistance and human toxicity. When one of the
targets is already a known antimalarial drug target, there are
increased chances that the given compound has an eﬀective
polyactivity proﬁle. Further to this, prior experimental evidence
for biological activity of the given compound against a
homologue of a P. falciparum protein increases the conﬁdence
of the predicted interaction between the two. We have, thus,
analyzed all predicted interactions taking all the above consi-
derations into account and in the heatmap of Fig. 2 we zoom
into the drug–target space of polyactive GSK compounds with
those P. falciparum proteins that fulﬁll these requirements.
For example, GSK compound hispidulin (CID 5281628) is
predicted to bind to three known antimalarial drug targets,
namely PF10_0084, PFE0520c and PFD0830w, the latter of
which has no known human homologue. Hispidulin is addi-
tionally predicted to bind to 28 other proteins of P. falciparum
that may also be important for the growth of the parasite, 15 of
which have no known human homologues. Hispidulin is a small
ﬂavonoid molecule from Artemisia vestita, a traditional Tibetan
medicinal plant, which is known for its anti-inﬂammatory,
antifungal, anti-proliferative, anti-thrombosis and anti-oxidative
activities.25 Recently, hispidulin has been studied and found
active on suppressing angiogenesis and pancreatic tumor
growth,25 while its activity on the P. falciparum screen conducted
by GSK makes it a very promising lead compound for further
evaluation and optimization.
Fig. 1 Predicted protein targets of the GlaxoSmithKline compounds in
the genome of P. falciparum. (A) Genomic location of predicted targets of
GSK compounds. The x-axis indicates the chromosomes 1 to 14 and the
y-axis indicates the location of coding genes in base pairs (bp). Red:
proteins coded at the sense-strand; black: proteins coded at the anti-sense
strand. (B) Target preference per chromosome. The y-axis shows the
diﬀerence between the predicted and expected number of protein targets
on each chromosome (corrected for the size of the chromosome). The bar
indicates 95% conﬁdence threshold, using Student’s t-test.
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On a subsequent analysis of the predicted drug–target inter-
actions, we used the recently compiled list of 30 experimentally
validated gene knockouts and phenotypes in P. falciparum by
Plata et al.26 This list of genes has resulted from targeted
inhibitions of enzymatic activities from drugs, and ﬁfteen of
them are also included in our list of 293 predicted targets.
Fig. 3 zooms into the results within this area of the druggable
proteome space of P. falciparum, where polyactive compounds
are predicted to target the experimentally validated essential
genes. Compounds in bold have shown in vitro activity against
both the wild type P. falciparum 3D7 and the D2d resistant
strain.16 For the majority of the ﬁfteen essential genes, there
are GSK compounds that contain more than one of them in
their activity proﬁle. Multiple polymorphisms in the genes
coding for antimalarial protein targets have been associated
with emergence of drug resistance, thus, having an activity
proﬁle that includes more than one essential protein, could be
an eﬃcient way for the drug to escape resistance. Only in the
case of PF14_0053 (ribonucleotide reductase), PF14_0425
(fructose-bisphosphate aldolase) and PFB0295w (adenylo-
succinate lyase) the polyactive compounds that are predicted
to bind to them do not have any other of the experimentally
validated essential proteins in their activity proﬁle. Surpris-
ingly, most of these compounds, e.g. all the compounds
targeting PF14_0053, have shown in vitro activity against both
the wild type and the resistant strain. Similarly, most of the
compounds from the cluster that is associated with the two
known drug targets PF10_0289 and PFD0830w seem to have
the right polyactivity proﬁle that manages to evade drug
resistance. One of them, CID 23618032, has been annotated
in ChemProt with experimental binding activity of 6.41 log
Fig. 2 Heatmap zoomed on the predicted interactions between poly-
active GSK compounds and prioritized P. falciparum proteins. Green:
protein target with no human homologue. Red: known experimental
activity with a non-human protein homologue of P. falciparum. Blue: rest
of predicted interactions within the subset of the 130 prioritized proteins.
The ﬁrst six targets on the left side of the x-axis are the known antimalarial
drug targets. On the top left, the structure of GSK compound hispidulin
(CID 5281628), whose interactions are included in the rectangle. The raw
data behind the heatmap are provided in File S3 (ESIw).
Fig. 3 Heatmap with predicted interactions between GSK compounds and P. falciparum experimentally validated essential proteins. Red:
validated experimental activity with a non-human protein homologue of P. falciparum. Blue: rest of predicted interactions. GSK compounds are
named according to PubChem CID. Protein names with asterisk are known antimalarial drug targets. Compounds in bold are active on both the
wild type and resistant strains. The structures of such compounds that are predicted to bind to two known drug targets are shown in the box on the
right. With the exception of PF14_0053, PF14_0425 and PFB0295w, only compounds that target at least two essential proteins have been included.
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(1/C) with a close homologue of PFD0830w, namely dihydro-
folate reductase from Mus musculus, which gives support to
the prediction. For these promising drug leads, one should
look deeper into their full activity proﬁle, as activity on non-
essential proteins should not be underestimated, because of
the emergence of ‘‘synthetic lethality’’, where genes that
are not essential individually are shown to be essential in
combination.
In addition to the above analyses, we used the recently
reconstructed genome-scale ﬂux balanced metabolic model of
P. falciparum26 to identify the perturbations caused in the
metabolism by the GSK compounds from a network level
perspective. In Fig. 4, we focus on the essential proteins from
Plata et al.26 and the 39 promising GSK compounds shown in
Fig. 3, advocating that disturbing the robustness of the meta-
bolic network over multiple biological pathways will increase
drug eﬀectiveness and prevent the development of drug resis-
tance. There is a cluster of compounds in the heatmap of Fig. 3
that are active on both wild type and resistant strains and are
predicted to bind to both known antimalarial drug targets
PF10_0289 and PFD0830w. Projecting these two targets on
the metabolic network of Fig. 4, we see that they are involved
in diﬀerent pathways, namely nucleotide metabolism and
biosynthesis of other secondary metabolites. It would, thus,
be of interest to look deeper into the speciﬁc metabolic path-
ways and investigate whether and how a simultaneous pertur-
bation of both could lead to parasite elimination and escape of
drug resistance.
Oﬀ-target interactions with the human proteome
We further studied potentially toxic oﬀ-target interactions with
human proteins and the 2512 polyactive GSK compounds,
extracting information from the Comparative Toxicogenomics
Database,27 one of the databases within ChemProt, where
drugs and environmental compounds are associated with toxi-
cologically important proteins. CDK has information for only
ﬁve GSK compounds that have been previously associated in
the literature with adverse and toxic eﬀects. Tryptanthrine (CID
73549) is reported to result in decreased expression of ABCB1
and TP53 that are involved in diﬀerent types of cancer. Olvanil
(CID 5311093) has been linked to TRPV1 oligomer formation
and increased expression of TAC1, both of which are related to
a number of esophagal and CNS diseases. Trimethoprim (CID
5578), a known antibacterial and currently in use as antimalarial
medication, has been associated with rhabdomyolysis, as well as
with antitumor activity in transitional cell carcinoma and
urinary bladder neoplasms, when administered together with
Sulfamethoxazole. Cycloheximide (CID 6197) has been
reported to interact with 300 diﬀerent human proteins asso-
ciated with a multitude of diseases, where malignant neoplasms
are ranked with the highest inference scores. Finally, pyrimeth-
amine (CID 4993), which is one of the safest drugs used in
malaria treatment, has been associated with decreased activity
of GSTP1 and CYP2C9 proteins and increased expression of
FOS and DDIT3 mRNA. FOS and GSTP1 are linked to drug
hypersensitivity, which is a well-known side eﬀect of the drug.28
Fig. 4 Visualization of the metabolic pathways of P. falciparum, where the 15 essential genes targeted by GSK compounds are participating. The
metabolic map was created from P. falciparum 3D7, species code: 36329. PF10-0322 has been omitted, as it could not be associated with a KEGG
ID. Protein names with asterisk are known antimalarial drug targets.
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As the available information in CTD in this particular area of
the chemical space is very limited, we subsequently explored the
eﬀect of the 2512 GSK compounds predicted to be poly-
active on humans via the integration of chemical–protein,
protein–protein and protein–disease associations. We considered
only chemical–protein interaction data with direct experimental
evidence in ChemProt, while protein complexes and complex–
disease associations were retrieved from our in-house human
interactome resource.29,30 There are in total 59 GSK compounds
with experimental activity data for 30 human proteins that form
38 non-redundant protein–protein interaction complexes (see
Files S4 and S5 (ESIw) for chemical–protein pairs and protein
complexes respectively). Fig. 5 illustrates the disease association
network due to known oﬀ-target interactions of the selected
GSK compounds. Cancer is the disorder class with the most
OMIMdiseases and the most associations with GSK compounds
(26 OMIM diseases and 167 associations in total). The classes of
neurological and dermatological disorders follow, with 73 and 64
associations with GSK compounds, respectively.
Methods
The druggable landscape of the P. falciparum proteome
The chemical structures of the 13533 GSK compounds were
retrieved from PubChem in SDF format, tagged with a unique
Compound ID (CID). In the cases where two chains were present,
only the longest one was kept. MACCS substructure ﬁngerprints
were generated with Open Babel (http://openbabel.org/). Struc-
tural similarity was assessed by the Tanimoto coeﬃcient using
a cut-oﬀ value of 0.85. Information on chemical–protein inter-
actions was extracted from ChemProt18 a repository of
700 000 unique chemicals and 30 578 proteins, assembled from
both proprietary and freely available databases, including
ChEMBL,31 BindingDB,32 PDSP Ki Database,33 DrugBank,34
PharmGKB,35 WOMBAT,36 WOMBAT-PK,36 PubChem
bioassay,37 CTD27 and STITCH.38
The protein sequences were retrieved from Batch Entrez
(http://www.ncbi.nlm.nih.gov/sites/batchentrez) and were blasted
against the proteome of P. falciparum’s (NCBI Genome Project
ID 148) with cut-oﬀ e-value of 103. The genomic location of
P. falciparum genes was obtained from http://plasmodb.org/
plasmo/. The preference for chromosomes was evaluated using
the Student’s t-test. GO-terms were assigned to the proteins
using Blast2GO (www.blast2go.org/). Heatmaps were created
in R, using the stats package.39 Hierarchical clustering with
Ward’s methods and default parameters was applied.
Oﬀ-target interactions with the human proteome
Protein–protein interactions were explored through an in-house
human interactome network based on experimental data from
Fig. 5 Disease association network of oﬀ-target interactions between GSK compounds and human proteins. Grey nodes: GSK compounds with experi-
mental binding aﬃnity with human proteins, colored nodes: OMIM IDs of targeted human proteins, color key: disorder classes according to Goh et al.53D
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humans and 21 model organisms.29,30 Using a probabilistic
conﬁdence-scoring scheme, all interactions have been validated
against a gold standard.40 The interactome network is com-
prised of 22 997 genes, and contains unique protein–protein
interactions derived from databases such as BIND,41 GRID,42
MINT,43 dip_full,44 HPRD,45 intact,46 mppi,47 MPact,48
Reactome49 and KEGG.50 Data were transferred between
organisms by using the Inparanoid orthology database.51
Protein complexes were subsequently associated to diseases
mentioned in OMIM52 by using the protein to OMIMmapping
displayed in GeneCards (http://www-bimas.cit.nih.gov/cards/)
database. Because a number of complexes are known to be
involved in diﬀerent diseases, a complex is allowed to be
associated with more than one disease. The enrichment of
proteins in complexes associated with the same OMIM disease
was calculated by using the annotations in GeneCards and the
signiﬁcance of the enrichment was evaluated by using a
hypergeometric test. The phenome-interactome resource currently
contains 2227 unique disease-related proteins from 1524
complexes, 350 of which are non-redundant. Disorder classes
were taken from Goh et al.53 and are associated to protein
targets via their OMIM IDs.
Conclusion
During the last 10–15 years, high-throughput technologies for
combinatorial and multi-parallel chemical synthesis and avail-
ability of large compound collections that often exceed one
million distinct chemical molecules have caused a fundamental
change in the drug discovery process conducted in pharma-
ceutical companies. In vivo phenotypic screening of small
molecule datasets is seen as a key element for ﬁlling the drug
discovery pipeline with new chemical compounds. GSK con-
ducted such a massive chemical screen (B2 000 000 chemical
entities) to identify growth inhibitors of P. falciparum, which
yielded 13 533 bioactive molecules. Approximately 8000 of
these plasmodial inhibitors were also active against the multi-
drug resistant strain. However, the identiﬁcation of the cellular
targets of such bioactive small molecules and the characteriza-
tion of their modes of action is a major bottleneck in drug
discovery.54 Identiﬁcation of the target would facilitate the
discovery of drug-cocktails (e.g. blocking a whole pathway
instead of one protein, or even multiple pathways), while
understanding the mode of action would allow the design of
eﬃcient drug molecules that can escape drug resistance.55
In our study we used the data from the screening of the
GSK library of compounds to draft a drug-relevant map of the
P. falciparum proteome, enriched with functional information.
By integrating data from a disease-centric chemical database
recently developed in our center (ChemProt18), we linked
B40% (4645 compounds) of the plasmodial inhibitors with
their putative protein targets. The 293 predicted targets con-
tained the six out of the seven veriﬁed targets for treating
P. falciparum-transmitted malaria, while the annotation of the
targets revealed established essential functions, e.g. nucleotide
binding,26 transporter activity,56 hypothesized essential functions,
e.g. protein kinase activity16 but also novel essential functions,
e.g. protein binding, transcriptional regulation and protein
modiﬁcation processes. From the 293 predicted targets, we identify
15 proteins as potential Achilles’ heel targets in the proteome
of P. falciparum that fulﬁll multiple criteria among essentiality
for growth, lack of homology with human proteins, lack of
resistance emergence and availability of experimental data that
support predicted binding to a GSK compound. Proteins
PF14_0053, PF10_0289 and PFD0830w appear to be espe-
cially interesting on the basis of evading drug resistance.
In the light of multi-target therapy being more eﬀective than
single-target therapy when treating infectious diseases, we
identiﬁed that compounds from the GSK collection, notably
CID 23618032, CID 44522264, CID 44531668 and CID
44531763, that are capable of escaping drug resistance, have
polypharmacology proﬁles that cover multiple essential targets
and perturb diﬀerent points of the parasite’s metabolic network.
Our results could also be used to elucidate drug synergy, and
assist in the selection of compounds with synergistic eﬀects that
could be used in a combinatorial antimalarial therapy.
However, we should not pass over the fact that both the
pharmaceutical industry and the regulatory authorities are
concerned by the risk of unexpected side eﬀects of compounds
that have been identiﬁed as drug leads against parasites based
only on high-throughput in vitro screening endeavors. In the
present study we predict potential oﬀ-target eﬀects on the
human host with associations to cancer, neurological and
dermatological disorders, based on integration of available
chemical–protein and protein–protein interaction data.
The development of novel, eﬃcient and inexpensive drugs is
an urgent priority. The report of Gamo et al.16 made for the
ﬁrst time accessible to the general research community com-
pounds that were previously proprietary to GSK and oﬀered
tremendous opportunities to develop the next generation of
antimalarial drugs. We believe that the present work contri-
butes signiﬁcantly to eﬀorts in identifying the most appropriate
targets and the most promising bioactive compounds from the
GSK library. Our work suggests that a large number of the
P. falciparum proteome is potentially druggable and could there-
fore serve as novel drug targets in the ﬁght against malaria. At
the same time, we prioritize compounds from the GSK library in
respect to their predicted interactions with the P. falciparum
proteome and metabolism, with the hope to provide interesting
lead compounds to medicinal chemists for further optimization.
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